Voprosy kliniki i farmakologicheskoy terapii bipolyarnogo affektivnogo rasstroystva


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Bipolar affective disorder (BAD) is a severe chronic mental disorder with different phases that requires a comprehensive approach to treatment, depending on the current phase, stage of therapy and clinical characteristics of the state. The review article describes the current approaches to the treatment of BAD at various stages (active, supporting and preventive therapy). Therapeutic schemes for treatment of depressive, manic, and mixed phases are presented. The features of administration and potentials for the combination of drugs of different pharmacological groups - mood stabilizers, antidepressants, antipsychotics, atypical antipsychotics as monotherapy and combined therapy of BAD - are analyzed.

Full Text

Restricted Access

References

  1. Аведисова А.С., Ястребов Д.В. Шизофрения и биполярное расстройство: вопросы клиники и терапии. М., 2013. 152 с.
  2. Мосолов С.Н. Основы психофармакотерапии. М., 1996. С. 164-80.
  3. Akiskal H.S. Diagnosis and classification of affective disorders: new insights from clinical and laboratory approaches. Psychiatric developments. 1983;1(2):123-60.
  4. Akiskal H.S., Pinto O. The evolving bipolar spectrum: prototypes I, II, III, and IV. Psychiatric Clinics North America. 1999; 22(3):51 7-34.
  5. Altamura A.C., Salvadoni D., Madaro D., et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12month openlabel study. J. Affect Disord. 2003;76:267-71.
  6. American Psychiatric Association (APA). Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry. 2002;159:1-50.
  7. Angst J. Zur Atiologie und Nosologie endogener depressiver Psychosen. Eine genetische, soziologische und klinische Studie. Monographien aus dem Gesamtgebiete der Neurologie und Psychiatrie. 1966; 112:1-18.
  8. Angst J., Gamma A., Benazzi F., et al. Diagnostic issues in bipolar disorder. Eur. Neuropsychopharm. 2003;13:43-50.
  9. Angst J., Stassen H.H., Clayton P.J., Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J. Affect. Disord 2002;68(2-3):167-81.
  10. Bowden C.L. A different depression: clinical distinctions between bipolar and unipolar depression. J. Affect. Disord. 2005;84(2-3):117-25.
  11. Bowden C.L., Grunze H., Mullen J., et al. A randomized, doubleblind, placebocontrolled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiat. 2005;66:111-21.
  12. Calabrese J.R., Keck P.E. Jr, Macfadden W., et al. A randomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry. 2005;162:1351-60.
  13. Calabrese J.R., Suppes T., Bowden C.L., et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal Study Group. J. Clin. Psychiatry. 2000;61 ( 11 ):841-50.
  14. El-Mallakh RS, Ghaemi SN. Bipolar depression: a comprehensive guide, 1st ed. American Psychiatric Publishing, 2006. 269 p.
  15. Figueira M.L., Akiskal H.S. Clinical Aspects of mania, 2009. P. 9-15.
  16. Fisher C, Broderick W. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? Psychiatric Bulletin. 2003;27:446-48.
  17. Fountoulakis K.N., Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol. 2008; 11:9991029.
  18. Fountoulakis K.N., Vieta E., Siamouli M., et al. Treatment of bipolar disorder: a complex treatment for a multifacet disorder. Annals. General Psychiatry. 2007;6:27.
  19. Frye M.A., Ketter T.A., Kimbrell T.A., et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J. Clin. Psychopharmacol. 2000;20(6):607-14.
  20. Geddes J.R., Burgess S., Hawton K., et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry. 2004;161 (2):217-22.
  21. Ghaemi S.N., Hsu D.J., Soldani F., Goodwin F.K. Antidepressants in bipolar disorder: the case for caution. Bipolar Disorders. 2003:5:421-33.
  22. Gijsman H.J., Geddes J.R., Rendell J.M., et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am. J. Psychiatry. 2004;161:1537-47.
  23. Goodwin F.K., Jamison K.R. Manic depressive ilness: bipolar disorders and reccurent depression. 2nd edition. New York: Oxford University Press, 2007. P. 12-49.
  24. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: revised second edition -recommendations from the British Association for Psychopharmacology. Consensus Group of the British Association for Psychopharmacology. J. Psychopharmacology. 2009;23(4):346-88.
  25. Goodwin G.M. Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. Br. J Psychiatry 1994;164(2):149-52.
  26. Hirsch feld M.A. Guideline watch: practice guideline for the treatment of patients with bipolar disorder, 2nd ed. In: American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders. 2004. P. 6-18.
  27. Hirsch feld R.M., Keck P.E. Jr, Kramer M., et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am. J. Psychiatry. 2004;161(6):1057-65.
  28. Hirshfewld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003;64:53-9.
  29. Janicak P.G., Keck P.E. Jr, Davis J.M., et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J. Clin. Psychopharmacol. 2001;21(4):360-08.
  30. Johnstone E.C.,Crow T.J.,Frith C.D., Owens D.G. The Northwick park «functional» psychosis study: diagnosis and treatment response. Lancet. 1988;2(8603):119-25.
  31. Keck J. Bipolar depression: a new role for atypical antipsychotics. Bipolar Disord. 2005:7(Suppl. 4):34-40.
  32. Kessler R.C., Berlund P., Dernler O., et al. Lifetime prevalence and age-of-onset distributions of DSM disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry. 2005;62:593-602.
  33. Leonhard K. Aufteilung der endogenen Psychosen. Berlin, 1957.
  34. Lusznat R.M., Murphy D.P., Nunn C.M. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br. J. Psychiatry. 1988;153:198-204.
  35. Macritchie K., Geddes J.R., Scott J., Haslam D., et al. Valproate for acute mood episodes in bipolar disorder (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
  36. Maj M., Akiskal H.S., Loppez-Ibor J.J., Sartorius N. Bipolar disorder, John Wiley & Sons, 2002;5:537.
  37. Mcintyre R.S., Brecher M., Paulsson B., et al. Quetiapine or haloperidol as monotherapy for biploar mania - a 12 week, doubleblind, randomised, parallel group, placebocontrolled trial. Eur. Neuropsychopharmacol. 2005;15:573-85.
  38. Meehan K., Zhang F., David S., et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. 2001;21 (4):389-97.
  39. Mitchell P.B. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord. 2004:28.
  40. Montgomery S.A., Cassano G.B. Management of bipolar disorder. CRC Press, 1996:96.
  41. Okuma T., Yamashita I., Takahashi R., Itoh H. Comparison of the antimanic efficacy of car-bamazepine and lithium carbonate by doubleblind controlled study. Pharmacopsychiatry. 1990;23(3): 143-50.
  42. Osby U., Brandt L., Correia N., Ekbom A., Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen. Psychiatry. 2001;58(9):844-50.
  43. Perlis R.H. Treatment of bipolar disorder: the evolving role of atypical antipsychotics. Am. J. Manag. Care. 2007;13:178-88.
  44. Perris C.A. Study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatrica Scandinavica. 1966; 2(Suppl. 194).
  45. Pini S., Abelli M., Cassano G.B. The role of que tiapine in the treatment of bipolar disorder. Expert Opin. Pharmacother. 2006;7:929-40.
  46. Rendell J.M., Gijsman H.J., Keck P., et al. Olanzapine alone or in combination for acute mania (Cochrane Review). In: the Cochrane Library, Issue 1, 2003. Oxford: Update Software.
  47. Sachs G.S., Grossman F., Ghaemi S.N., et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am. J. Psychiatry. 2002; 159(7): 1146-54.
  48. Sachs G., Chengappa K.N., Suppes T., et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6(3):213-23.
  49. Scottish Intercollegiate Guidelines Network (SIGN). Bipolar affective disorder. A national clinical guideline. Edinburgh, 2005. P. 41.
  50. Small J.C., Klapper M.H., Milstein V., et al. Carbamazepine compared with lithium in the treatment of mania. Arch. Gen. Psychiatry. 1991;48:915-21.
  51. Stratta P., de Cataldo S., Mancini G., et al. Quetiapine as adjunctive treatment of a case of rapidcycling bipolar disorder with comorbidity. Hum. Psychopharmacol. Clin. Exp. 2003;18:559-60.
  52. Suppes T., Dennehy E.B., Hirschfeld R.M. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar disorder. J. Clin. Psychiatry. 2005;60:870-86.
  53. Thase M.E., Macfadden W., Weisler R.H., et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study (the BOLDER II study). J. Clin. Psychopharmacol. 2006;26:600-09.
  54. Tohen M., Greil W., Calabrese J.R., et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-Month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry. 2005; 162:1281 -90.
  55. Tohen M., Zhang F., Keck P.E., et al. Olanzapine versus haloperidol in schizoaffective disorder, bipolar type. J. Affective Disorders. 2001;67(1-3):133-40.
  56. Vieta E. The role of third generation anticonvulsants in the treatment of bipolar disorder. Clin. Neuropsichiatry. 2004;1:159-64.
  57. Visser H.M., Van Der Mast R.C. Blom A. Bipolar disorder, antidepressants and induction of (hypo)mania: a systematic review. Tijdschrift voor Psychiatrie. 2002;44(9): 599-608.
  58. Wassef A.A., Winkler D.E., Roache A.L., et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasiexperimental clinical trial involving psychiatric admissions. Am. J. Psychiatry. 2005;162(2): 330-39.
  59. Weisler R.H., Kalali A.H., Ketter T.A. SPD417 Study Group. A multicenter, randomized, double- blind, placebo-controlled trial of extend-ed-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J. Clin. Psychiatry. 2004;65(4):478-84.
  60. Yatham L.N. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disorders. 2003; 5(Suppl. 2):7-19.
  61. Yatham L.N., Kennedy S.H., O'Donovan C., et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11:225-55.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies